Catalyst Pharmaceuticals, Inc. (CPRX)

NASDAQ: CPRX · Delayed Price · USD
6.88
0.01 (0.15%)
At close: May 25, 2022 4:00 PM
7.10
0.22 (3.20%)
Pre-market:May 26, 2022 7:32 AM EDT
Market Cap707.13M
Revenue (ttm)153.72M
Net Income (ttm)45.06M
Shares Out102.78M
EPS (ttm)0.42
PE Ratio16.38
Forward PE10.54
Dividendn/a
Ex-Dividend Daten/a
Volume998,317
Open6.84
Previous Close6.87
Day's Range6.62 - 6.94
52-Week Range4.81 - 8.65
Beta1.29
AnalystsBuy
Price Target11.17 (+62.4%)
Earnings DateMay 10, 2022

About CPRX

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis, and spinal muscular atroph...

IndustryBiotechnology
IPO DateNov 8, 2006
CEOPatrick McEnany
Employees76
Stock ExchangeNASDAQ
Ticker SymbolCPRX
Full Company Profile

Financial Performance

In 2021, CPRX's revenue was $140.83 million, an increase of 18.27% compared to the previous year's $119.07 million. Earnings were $39.48 million, a decrease of -47.35%.

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for CPRX stock is "Buy." The 12-month stock price forecast is 11.17, which is an increase of 62.35% from the latest price.

Price Target
$11.17
(62.35% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Catalyst Pharmaceuticals to Participate in Two Upcoming Investor Conferences

CORAL GABLES, Fla., May 17, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and com...

1 week ago - GlobeNewsWire

Catalyst Pharmaceuticals (CPRX) Q1 Earnings Miss, Revenues Up Y/Y

Catalyst's (CPRX) first-quarter 2022 earnings miss estimates while revenues meet the same.

2 weeks ago - Zacks Investment Research

Catalyst Pharmaceutical (CPRX) Misses Q1 Earnings and Revenue Estimates

Catalyst (CPRX) delivered earnings and revenue surprises of -14.29% and 0.19%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

2 weeks ago - Zacks Investment Research

Catalyst Pharmaceuticals Reports Record First Quarter 2022 Financial Results And Provides Corporate Update

Achieved Record Revenues of more than $43 Million, a 42.7% Increase YoY

2 weeks ago - GlobeNewsWire

Drug/Biotech Stocks' Q1 Earnings on May 10: EXEL, BHC & More

Let's look at the five biotech/drug companies that are slated to release quarterly results on May 10.

Other symbols:BHCEPZMEXELRETA
2 weeks ago - Zacks Investment Research

Catalyst Pharmaceuticals to Report First Quarter 2022 Financial Results on May 10, 2022

The Company to Host a Conference Call and Webcast on May 11, 2022, at 8:30 AM ET The Company to Host a Conference Call and Webcast on May 11, 2022, at 8:30 AM ET

1 month ago - GlobeNewsWire

Catalyst Pharmaceutical (CPRX) is a Top-Ranked Momentum Stock: Should You Buy?

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

1 month ago - Zacks Investment Research

7 Smart Stocks to Buy Now Under $10

There are always good stocks to buy somewhere. What you should be focused on is finding the smart stocks that add value to your portfolio.

Other symbols:ARCOGTEKOSLNDTHOBE
1 month ago - InvestorPlace

Catalyst (CPRX) Q4 Earnings Lag Estimates, Revenues Rise Y/Y

Catalyst's (CPRX) fourth-quarter 2021 earnings miss estimates while revenues slightly beat the mark.

2 months ago - Zacks Investment Research

Catalyst Pharmaceutical (CPRX) Q4 Earnings Lag Estimates

Catalyst (CPRX) delivered earnings and revenue surprises of -25% and 0.37%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Catalyst Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

Total 2021 Revenues Increased Approximately 18% YoY to $141 Million

2 months ago - GlobeNewsWire

Catalyst Pharmaceuticals and KYE Pharmaceuticals Announce a Second Favorable Canadian Federal Court Ruling Setting As...

CORAL GABLES, Fla., March 11, 2022 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, ...

2 months ago - GlobeNewsWire

Catalyst (CPRX) Skyrockets 110% Over a Year: Here's Why

Catalyst's (CPRX) stock price has more than doubled in the past year, driven by its sole marketed drug, Firdapse, approved for the treatment of Lambert-Eaton Myasthenic Syndrome in adults.

2 months ago - Zacks Investment Research

Catalyst Pharmaceutical (CPRX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Catalyst (CPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

Catalyst Pharmaceuticals Named Among Forbes 2022 America's Best Small Companies

The Company Ranked 65th of More Than 1,000 Companies Assessed The Company Ranked 65th of More Than 1,000 Companies Assessed

2 months ago - GlobeNewsWire

Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2021 Financial Results on March 16, 2022

The Company Will Host a Conference Call and Webcast on March 17, 2022, at 8:30 AM ET The Company Will Host a Conference Call and Webcast on March 17, 2022, at 8:30 AM ET

2 months ago - GlobeNewsWire

4 Small Drug Stocks That Appear to Be Solid Bets in a Challenging Industry

Some business disruption due to COVID-19 was felt by the Medical-Drugs industry players in 2021. CPRX, KDNY, ASRT and SGTX may prove to be good additions to one's portfolio.

Other symbols:ASRTKDNYSGTX
2 months ago - Zacks Investment Research

Catalyst Pharmaceuticals Further Strengthens FIRDAPSE® U.S. Patent Portfolio

Three New Patents Covering Additional Patient Amifampridine Metabolizer Types have been Allowed and will Issue in March 2022

2 months ago - GlobeNewsWire

Wall Street Analysts Predict a 25% Upside in Catalyst (CPRX): Here's What You Should Know

The average of price targets set by Wall Street analysts indicates a potential upside of 25.2% in Catalyst (CPRX). While the effectiveness of this highly sought-after metric is questionable, the positiv...

2 months ago - Zacks Investment Research

What Makes Catalyst (CPRX) a Good Fit for "Trend Investing"

Catalyst (CPRX) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

2 months ago - Zacks Investment Research

Catalyst Pharmaceuticals Teams Up with Patients and Advocacy Groups to Ring Nasdaq Opening Bell on Rare Disease Day 2022

Ceremony Recognizes Importance of Biopharma Industry and Advocacy Group Collaboration to Address Needs for New Treatments in Orphan and Rare Disorders

3 months ago - GlobeNewsWire

Catalyst Pharmaceuticals to Launch LEMS Aware Podcast on Rare Disease Day 2022

Initiative Part of Expansion of Education and Awareness Activities for Lambert-Eaton Myasthenic Syndrome Community Initiative Part of Expansion of Education and Awareness Activities for Lambert-Eaton My...

3 months ago - GlobeNewsWire

Here's Why Momentum in Catalyst (CPRX) Should Keep going

Catalyst (CPRX) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

3 months ago - Zacks Investment Research

Wall Street Analysts See a 33% Upside in Catalyst (CPRX): Can the Stock Really Move This High?

The consensus price target hints at a 33.3% upside potential for Catalyst (CPRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate r...

3 months ago - Zacks Investment Research

Catalyst's (CPRX) Stock Up on 2022 Guidance for Firdapse

Catalyst Pharmaceuticals (CPRX) reports preliminary sales figures for the fourth quarter. The company also provides its revenue guidance for 2022.

3 months ago - Zacks Investment Research